title: Extending the Time Window for Endovascular and Pharmacological Reperfusion.
abstract: Pharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7-15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.
authors.affiliation: Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.|Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: Nils
authors.initials: N
authors.lastname: Henninger
authors.affiliation: Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. mfisher5@bidmc.harvard.edu.|Division of Stroke and Cerebrovascular Diseases, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. mfisher5@bidmc.harvard.edu.
authors.forename: Marc
authors.initials: M
authors.lastname: Fisher
mesh_terms: D000818:Animals; D057510:Endovascular Procedures / Q000379:methods*; D006801:Humans; D015427:Reperfusion Injury / Q000628:therapy*; D020521:Stroke / Q000628:therapy*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D010959:Tissue Plasminogen Activator
keywords: Animal modeling; Endovascular; Imaging; Ischemic stroke; Neuroprotection; Recanalization; Reperfusion injury; Thrombolysis; Time window; Tissue-type plasminogen activator